Chrome Extension
WeChat Mini Program
Use on ChatGLM

Integrating Genetic Subtypes with PET Scan Monitoring to Predict Outcome in Diffuse Large B-cell Lymphoma

Matias S. Mendeville,Jurriaan JanssenBauke Ylstra,Daphne de Jong

NATURE COMMUNICATIONS(2025)

Amsterdam UMC | Univ Hosp Schleswig Holstein | Univ Groningen | Univ Med Ctr Rotterdam | Univ Basel | Univ Hosp Essen

Cited 0|Views2
Abstract
Next Generation Sequencing-based subtyping and interim- and end of treatment positron emission tomography (i/eot-PET) monitoring have high potential for upfront and on-treatment risk assessment of diffuse large B-cell lymphoma patients. We performed Dana Farber Cancer Institute (DFCI) and LymphGen genetic subtyping for the HOVON84 (n = 208, EudraCT-2006-005174-42) and PETAL (n = 204, EudraCT-2006-001641-33) trials retrospectively combined with DFCI genetic data (n = 304). For all R-CHOP treated patients (n = 592), C5/MCD- and C2/A53-subtypes show significantly worse outcome independent of the international prognostic index. For all subtypes, adverse prognostic value of i/eot-PET-positive status is confirmed. Consistent with frequent primary refractory disease, only 67% C2 patients become eot-PET-negative versus 81-88% for other subtypes. Indicative of high relapse rates, outcome of C5 i/eot-PET-negative patients remains significantly worse in HOVON-84, which trend validates in the PETAL and SAKK38-07 trials (NCT00544219). These results show the added value of integrated genetic subtyping and PET monitoring for prognostic stratification and subtype-specific trial design.
More
Translated text
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:论文通过整合遗传亚型和PET扫描监测,预测弥漫大B细胞淋巴瘤患者的治疗效果,提出了一种新的预后分层方法。

方法】:使用下一代测序技术进行遗传亚型分类,并结合治疗过程中期和结束时的正电子发射断层扫描(i/eot-PET)进行监测。

实验】:对HOVON84(n = 208)和PETAL(n = 204)临床试验的遗传数据进行了回顾性分析,结合了DFCI遗传数据(n = 304),共分析了592名接受R-CHOP治疗的患者的数据。实验结果表明,C5/MCD-和C2/A53亚型预后较差,且i/eot-PET阳性状态对预后具有负面影响。C2亚型患者中,仅有67%在治疗结束时PET扫描呈阴性,而其他亚型为81-88%。在HOVON-84试验中,C5亚型患者即使i/eot-PET阴性,预后仍显著较差,这一趋势在PETAL和SAKK38-07试验中得到验证。